Actinium Pharmaceuticals ... (ATNM)
Actinium Pharmaceuticals Statistics
Share Statistics
Actinium Pharmaceuticals has 31.2M shares outstanding. The number of shares has increased by 12.36% in one year.
| Shares Outstanding | 31.2M |
| Shares Change (YoY) | 12.36% |
| Shares Change (QoQ) | 0.13% |
| Owned by Institutions (%) | 24.59% |
| Shares Floating | 30.4M |
| Failed to Deliver (FTD) Shares | 507 |
| FTD / Avg. Volume | 0.16% |
Short Selling Information
The latest short interest is 1.45M, so 4.66% of the outstanding shares have been sold short.
| Short Interest | 1.45M |
| Short % of Shares Out | 4.66% |
| Short % of Float | 4.78% |
| Short Ratio (days to cover) | 5.72 |
Valuation Ratios
The PE ratio is -2.77 and the forward PE ratio is -1.85. Actinium Pharmaceuticals's PEG ratio is -0.07.
| PE Ratio | -2.77 |
| Forward PE | -1.85 |
| PS Ratio | 1668.5 |
| Forward PS | 0.5 |
| PB Ratio | 3.72 |
| P/FCF Ratio | -2.85 |
| PEG Ratio | -0.07 |
Enterprise Valuation
Actinium Pharmaceuticals Inc. has an Enterprise Value (EV) of 60.58M.
| EV / Earnings | -1.24 |
| EV / Sales | 747.96 |
| EV / EBITDA | -1.18 |
| EV / EBIT | -1.17 |
| EV / FCF | -1.28 |
Financial Position
The company has a current ratio of 9.21, with a Debt / Equity ratio of 0.06.
| Current Ratio | 9.21 |
| Quick Ratio | 9.21 |
| Debt / Equity | 0.06 |
| Total Debt / Capitalization | 5.49 |
| Cash Flow / Debt | -22.4 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.34% and return on capital (ROIC) is -134.89%.
| Return on Equity (ROE) | -1.34% |
| Return on Assets (ROA) | -0.6% |
| Return on Capital (ROIC) | -134.89% |
| Revenue Per Employee | $2,189.19 |
| Profits Per Employee | $-1,319,405.41 |
| Employee Count | 37 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -76.57% in the last 52 weeks. The beta is 0.11, so Actinium Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.11 |
| 52-Week Price Change | -76.57% |
| 50-Day Moving Average | 1.23 |
| 200-Day Moving Average | 2.69 |
| Relative Strength Index (RSI) | 77.85 |
| Average Volume (20 Days) | 313.79K |
Income Statement
In the last 12 months, Actinium Pharmaceuticals had revenue of 81K and earned -48.82M in profits. Earnings per share was -1.83.
| Revenue | 81K |
| Gross Profit | 81K |
| Operating Income | -51.92M |
| Net Income | -48.82M |
| EBITDA | -51.13M |
| EBIT | -51.92M |
| Earnings Per Share (EPS) | -1.83 |
Balance Sheet
The company has 76.68M in cash and 2.11M in debt, giving a net cash position of 74.56M.
| Cash & Cash Equivalents | 76.68M |
| Total Debt | 2.11M |
| Net Cash | 74.56M |
| Retained Earnings | -337.58M |
| Total Assets | 82.11M |
| Working Capital | 71.77M |
Cash Flow
In the last 12 months, operating cash flow was -47.34M and capital expenditures -153K, giving a free cash flow of -47.49M.
| Operating Cash Flow | -47.34M |
| Capital Expenditures | -153K |
| Free Cash Flow | -47.49M |
| FCF Per Share | -1.78 |
Margins
Gross margin is 100%, with operating and profit margins of -64.1K% and -60.27K%.
| Gross Margin | 100% |
| Operating Margin | -64.1K% |
| Pretax Margin | -60.27K% |
| Profit Margin | -60.27K% |
| EBITDA Margin | -63.12K% |
| EBIT Margin | -64.1K% |
| FCF Margin | -58.63K% |
Dividends & Yields
ATNM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -98.39% |
| FCF Yield | -81.84% |
Analyst Forecast
The average price target for ATNM is $5, which is 168.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 168.8% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Aug 11, 2020. It was a backward split with a ratio of 1:30.
| Last Split Date | Aug 11, 2020 |
| Split Type | backward |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | -6.38 |
| Piotroski F-Score | 2 |